Zynerba Pharma CS (ZYNE)

$4.64 0.03 (0.65%)

16:00 EST ZYNE Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 62.92M

PE Ratio -1.66

EPS -2.79

Volume (Avg. Vol.) 564,429

Day's Range 4.45 - 4.74

52-Week Range 2.55 - 7.45

Dividend & Yield N/A (N/A)

ZYNE Stock Predictions, Articles, and Zynerba Pharma CS News

From InvestorPlace
From the Web

7 Stocks to Buy With 100% Upside Potential

By Maya Sasson, Writer, TipRanks Oct 23, 2019

Investors are looking for the stocks that have the potential to lift their portfolios to new heights. These investments are the stocks with the strongest long-term growth narratives, capable of delivering massive returns.

Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About

By David Moadel, InvestorPlace Contributor Sep 17, 2019

Thinking about investing in medical cannabis? ZYNE stock is a lesser-known gem with transformative potential.

5 Cannabis Stocks Set for Massive Gains

By Harriet Lefton, Writer, TipRanks Aug 26, 2019

We are on the brink of a massive market opportunity. For instance, a new report by Grand View Research reveals that the global legal marijuana market size is expected to reach $66.3 billion by the end of 2025.

3 Marijuana Stocks to Play the Future of Cannabis Medicine

By Aaron Levitt, InvestorPlace Contributor Aug 6, 2019

Looking for the real gains among the marijuana stocks? The key is to focus on firms using cannabis in medicine. Here are three biotech stocks moving headfirst into cannabis medicine.

Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder

By Bret Kenwell, InvestorPlace Contributor Jun 11, 2019

Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.

7 Marijuana Stocks to Play the CBD Trend

By Tom Taulli, InvestorPlace Writer & IPO Playbook Editor May 23, 2019

The CBD trend is heating up as its multiple uses gain traction and laws enable its use. Here are seven marijuana stocks to buy.

5 Cannabis Stocks Set to Skyrocket — According to Wall Street’s Top Analysts

By Harriet Lefton, Writer, TipRanks Apr 1, 2019

Investors have heard a ton about cannabis stocks and their ridiculous valuations. But Wall Street analysts say these pot stocks still have a lot of upside ahead.

Zynerba Stock Is Marijuana-Adjacent Play Worth a Look

By Ian Bezek, InvestorPlace Contributor Feb 7, 2019

Zynerba has a CBD gel that looks like a promising treatment for various neurological diseases. What does it mean for ZYNE stock?

Zynerba Pharmaceuticals News: Why ZYNE Stock Is Soaring Today

By William White, InvestorPlace Writer Jan 29, 2019

There's some positive Zynerba Pharmaceuticals news concerning ZYNE stock on Tuesday that has it soaring to incredible heights.

2 Marijuana Biotechs to Watch

By Matt McCall, Editor, MoneyWire Oct 1, 2018

Things may be looking up for marijuana stocks, as a cannabidiol (CBD)-based drug was rescheduled to Schedule 5. These 2 should profit next.

Zynerba Pharmaceuticals Continues Its 3-Day Rally

By William White, InvestorPlace Writer Aug 30, 2018

Zynerba Pharmaceuticals (ZYNE) stock isn't done with its recent rally yet as the stock continues to climb higher on Thursday.

Market Roasts Shares of Zynerba Pharmaceuticals

By Chris Lau, InvestorPlace Contributor Jul 24, 2018

Zynerba's stock sank after the company issued shares at $8. This validated the bearish bets against the stock. What should investors expect next?

The 10 Best Stocks for 2017 Contest — The Experts Pull Into the Homestretch!

By Jessica Loder, InvestorPlace Assistant Editor Oct 2, 2017

InvestorPlace's Best Stocks Contest is entering the homestretch! Here's how our experts' picks are holding up through the third quarter.

3 Stocks to Watch on Monday: Alphabet Inc (GOOGL), Zynerba Pharmaceuticals Inc (ZYNE) and Sony Corp (ADR) (SNE)

By Karl Utermohlen, InvestorPlace Writer Aug 7, 2017

Zynerba Pharmaceuticals (ZYNE) crashes by nearly half, Alphabet (GOOGL) responds to anti-diversity letter and Sony (SNE) suffers yet another box-office disappointment.